Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation

Parkinson's disease (PD) is one of the most common neurodegenerative disorders that is implicated in aging populations. As numerous developed nations are experiencing progressively aging populations today, there is a heightened propensity for the occurrence of PD cases. Alpha-synuclein (alpha-syn) aggregation has been considered to be the pivotal mechanism leading to PD pathogenesis. Thus, early diagnostic and therapeutic strategies targeting the misfolded alpha-syn protein can potentially improve the prognosis of PD. With rapid advancements in nanotechnology in the last decade, effective solutions to various neurodegenerative and oncological diseases have been suggested. This review will explore the current innovations in nanotechnology that target the alpha-syn aggregation pathway, and reinstate the promise they hold as effective early diagnostic and therapeutic solutions to PD.

Automated summary

Parkinson's disease is a common neurodegenerative disorder associated with aging populations. The aggregation of alpha-synuclein has been identified as a key mechanism in the pathogenesis of PD. Rapid advancements in nanotechnology present promising solutions for early diagnosis and treatment of PD.